Healthcare Industry News: NuVasive
News Release - May 25, 2016
Ceterix Announces Appointment of Edward Graubart as Vice President, SalesSeasoned Executive Brings Wealth of Sales, Product Launch Experience
MENLO PARK, Calif.--(Healthcare Sales & Marketing Network)--Ceterix® Orthopaedics, Inc., a developer of novel surgical tools that improve a surgeon’s ability to perform minimally invasive orthopaedic procedures, today announced that Edward Graubart has joined the company as vice president of sales.
Mr. Graubart joins Ceterix from NuVasive, Inc., a medical device company focused on developing products for minimally invasive spine procedures, where he served most recently as vice president of sales for the Western United States, supporting NuVasive’s growth from $38M in 1995 to over $800M in 2015. Prior to NuVasive, Mr. Graubart was director of Spine Arthroplasty at DePuy Spine, Inc. where he was part of an elite team hired to train and support the introduction of the first lumbar artificial disc approved in the United States. Mr. Graubart has also served in various sales and leadership roles during his 14-year tenure at EBI Medical Systems (A Biomet Company).
“We are thrilled to welcome Ed to the Ceterix family,” said John McCutcheon, president and CEO of Ceterix Orthopaedics. “His 27 years of orthopaedic, spine and trauma sales experience, as well as the distinct skill set of launching and selling unique medical devices, will lend tremendous value to Ceterix.”
“Ceterix offers a unique solution to a common orthopaedic problem – addressing complex meniscal tears in a way that preserves, rather than removes, the meniscus, with the goal of avoiding arthritis and other complications later in life,” said Mr. Graubart. “I’m excited about the opportunity to bring the company’s innovative NovoStitch Plus device to orthopaedic surgeons and to patients with knee injuries.”
Patients with meniscus tears often undergo meniscectomy – total or partial removal of the meniscus – due to the difficulty of access and limitations of current arthroscopic instruments. However, meniscectomy significantly increases the risk of arthritis or total knee replacement later in life.1 In contrast, meniscus repair, a procedure in which the tear is sutured and allowed to heal naturally, is associated with improved long-term outcomes and overall cost savings relative to meniscectomy.2
Ceterix’s NovoStitch Plus meniscal repair system allows orthopaedic surgeons to address horizontal, radial, and other complex meniscal tears in ways not previously possible. The system enables the placement of a circumferential compression stitch around the meniscus, providing uniform compression during healing. The newest device incorporates a pre-loaded suture implant, a design innovation that improves ease of use and cuts the number of procedure steps by more than half.
About Ceterix Orthopaedics
Ceterix Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue injuries such as meniscus tears, hip and shoulder labrum tears, and rotator cuff tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel meniscus repair device enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The company is based in Menlo Park, Calif. and is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures. For more information, please visit www.ceterix.com.
1 Papalia, R. et. al. Meniscectomy as a risk factor for knee osteoarthritis: a systematic review. British Medical Bulletin. 2011; 99:89 – 106.
2 Feeley, B. et. al. The Cost-Effectiveness of Meniscal Repair versus Partial Meniscectomy: A Model-based Projection for the United States Healthcare System. The Knee. 2016 May 2;epub ahead of print.
Source: Ceterix Orthopaedics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.